New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women

Journal of Infectious Diseases

Volumn 206, Issue 10, 2012, Pages 1612-1621

  Fowkes, Freya Ji ^a,b,d   McGready, Rose ^f,g,h   Cross, Nadia J ^a,d   Hommel, Mirja ^a,d   Simpson, Julie A ^b   Elliott, Salenna R ^d   Richards, Jack S ^a,c,d   Lackovic, Kurt ^d   Viladpai Nguen, Jacher ^f   Narum, David ⁱ   Tsuboi, Takafumi ^j   Anders, Robin F ^e   Nosten, François ^f,g,h   Beeson, James G ^a,d  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

^f SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j EHIME UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIBODY; PARASITE ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INNATE IMMUNITY; LONGEVITY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MEASLES; MEROZOITE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREGNANT WOMAN; PRIORITY JOURNAL;

ADULT; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; CASE-CONTROL STUDIES; CHLOROQUINE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; THAILAND; YOUNG ADULT;

EID: 84867716783     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis566     Document Type: Article

References (34)

1. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. Emerg Infect Dis 2006; 12:1638-43.
2. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS medicine 2010; 7:e1000221.
3. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64:28-35.
4. Nosten F, McGready R, Simpson JA, et al. Effects of Plasmodium vivax malaria in pregnancy. Lancet 1999; 354:546-9.
5. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunology 2006; 28:51-60.
6. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS medicine 2010; 7:e1000218.
7. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum Vaccin 2010; 6:84-9.
8. Brabin BJ. The risks and severity of malaria in pregnant women. Applied field research in malaria. Geneva: WHO, 1991:1-34.
9. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science (New York, NY 1996; 272:1502-4.
10. Beeson JG, Brown GV, Molyneux ME, Mhango C, Dzinjalamala F, Rogerson SJ. Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. J Infect Dis 1999; 180:464-72.
11. Salanti A, Dahlback M, Turner L, et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 2004; 200:1197-203.
12. Beeson JG, Ndungu F, Persson KE, et al. Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa. The American Journal of Tropical Medicine and Hygiene 2007; 77:22-8.
13. Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 1991; 85:424-9.
14. Villegas L, McGready R, Htway M, et al. Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. Trop Med Int Health 2007; 12:209-18.
15. Dubowitz L. A clinical manual: gestational age of the newborn. USA: Addison Wesley, 1977.
16. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001; 69:3286-94.
17. Richards JS, Stanisic DI, Fowkes FJ, et al. Association between Naturally Acquired Antibodies to Erythrocyte-Binding Antigens of Plasmodium falciparum and Protection from Malaria and High-Density Parasitemia. Clin Infect Dis 2010; 51:e50-60.
18. Reed MB, Caruana SR, Batchelor AH, Thompson JK, Crabb BS, Cowman AF. Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion. Proc Natl Acad Sci USA 2000; 97:7509-14.
19. Stanisic DI, Richards JS, McCallum FJ, et al. IgG subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infection and Immunity 2009; 77:1165-74.
20. Roussilhon C, Oeuvray C, Muller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS medicine 2007; 4:e320.
21. Avril M, Cartwright MM, Hathaway MJ, et al. Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect Immun 2010; 78:2248-56.
22. Yildiz Zeyrek F, Palacpac N, Yuksel F, et al. Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One 2011; 6:e28126.
23. StataCorp. Stata statistical software: release 11. College Station, Texas: StataPress, 2009; 87:377-90.
24. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunology and Cell Biology 2009.
25. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. The New England Journal of Medicine 2007; 357:1903-15.
26. Wykes M, Good MF. Memory B cell responses and malaria. Parasite immunology 2006; 28:31-4.
27. Weiss GE, Traore B, Kayentao K, et al. The Plasmodium falciparumspecific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog 2010; 6:e1000912.
28. Wipasa J, Suphavilai C, Okell LC, et al. Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 2010; 6:e1000770.
29. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malaria Journal 2007; 6:82.
30. Akpogheneta OJ, Duah NO, Tetteh KK, et al. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infection and Immunity 2008; 76:1748-55.
31. Hviid L. The case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malaria. Expert Rev Vaccines 2011; 10:1405-14.
32. McGready R, Davison BB, Stepniewska K, et al. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. The American Journal of Tropical Medicine and Hygiene 2004; 70:398-407.
33. WHO. World malaria report 2010. Geneva: WHO Press, World Health Organization, 2010:1-63.
34. Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 2010; 10:51-9.